Deceptive Warning Labels at Root of New Lipitor Lawsuits

New lawsuits against Pfizer continue to pour in claiming that their blockbuster statin drug, Lipitor, caused type 2 diabetes. When Lipitor was first approved in 1996, it was heralded as a breakthrough in controlling and reducing high levels of cholesterol. The drug works by preventing the creation of cholesterol in the body, which in turn lowers the prominence of LDL, the “bad cholesterol”. Yet in the quest to control heart disease and reduce the risk of atherosclerosis, Lipitor has put its patients at risk for developing another long-term illness: type 2 diabetes.

Studies as early as 2004 found that high Lipitor doses translated into worsening glycemic control in patients. Studies in 2010 and 2011 also pointed to an increased risk of type 2 diabetes and Lipitor. In January 2012, the Women’ Health Initiative statin study was published which showed that post-menopausal women who were taking statin drugs, like Lipitor, had a 50% higher risk of developing diabetes than those who were not on statin drugs.

In light of that new data, Pfizer updated the labels on their Lipitor drugs in February 2012. Yet in spite of this new label warning change, plaintiffs allege that the connection between Lipitor and type 2 diabetes was still deliberately unclear. Why? Read the warning for yourself:

“Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including Lipitor.”

Plaintiffs that are a part of new lawsuits across the country allege that Pfizer deliberately used doublespeak to muddy the waters surrounding the connection between Lipitor and type 2 diabetes. Had the warning label been clear to the average consumer, these plaintiffs may not have chosen to take Lipitor and thus avoided being diagnosed with a lifelong condition, such as type 2 diabetes.

The Lipitor MDL (MDL No. 2502) is in US District Court, District of South Carolina. Patients who have taken Lipitor and who have also been diagnosed with type 2 diabetes may be eligible to participate in this class action lawsuit. To find out more about Lipitor litigation across the country, contact the experienced Philadelphia dangerous drug lawyers at Golomb Legal today.

National Lipitor Lawsuit Lawyers

The national dangerous drug lawsuit attorneys at Golomb Legal are currently investigating Lipitor lawsuits claims. If you or someone you love has been diagnosed with Type 2 Diabetes after being prescribed Lipitor, call us at 1-800-355-3300 or 1-215-985-9177 immediately to evaluate your case.

Our experienced litigation lawyers have represented injured consumers across the United States in their quest for justice. We believe in holding negligent pharmaceutical companies responsible for their deceptive advertising actions and dangerous products. To learn more about your legal options or to schedule a free consultation call the Philadelphia class action lawyers at Golomb Legal today at 1-800-355-3300 or 1-215-985-9177 or fill out our confidential Contact Form.

The national class action lawyers at Golomb Legal have successfully represented individuals throughout the United States.